In addition to the clinical potential of targeting APE1 in combinatorial therapies, it has been demonstrated that APE1 nuclease inhibitors induce the SL of cancer cells that are deficient in DNA DSB repair, i.e., BRCA or ataxia telangiectasia mutated (ATM) defective cell models [73]. This evidence concerns the gene APEX1 and cancer.